Oral cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris.
Open Access
- 1 January 1990
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 70 (1) , 77-79
- https://doi.org/10.2340/00015555707779
Abstract
In a prospective open study, seven patients with persistent pustulosis palmaris et plantaris were treated with oral Cyclosporin A (CsA). Clinical efficacy was assessed on a semi-quantitative 0-4 point scale for erythema, desquamation, induration and pustulation. CsA controlled skin lesions in doses ranging from 1.1 to 6.1 mg/kg body weight/day. Clinical side effects included renal impairment, nausea and tiredness. Rapid recurrence of the skin lesions was observed on withdrawal or insufficient treatment with the drug.This publication has 6 references indexed in Scilit:
- Long-term cyclosporin for psoriasisBritish Journal of Dermatology, 1989
- SQUAMOUS-CELL CARCINOMAS IN RELATION TO CYCLOSPORINE THERAPY OF NONMALIGNANT SKIN DISORDERS1989
- Cyclosporine improves psoriasis in a double-blind studyJAMA, 1986
- Production of LTB4-like Chemotactic Arachidonate Metabolites from Human KeratinocytesJournal of Investigative Dermatology, 1985
- Effect of Cyclosporin A on Human Neutrophil and Monocyte FunctionScandinavian Journal of Immunology, 1985
- The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosisBritish Journal of Dermatology, 1985